Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 11:13 AM
Ignite Modification Date: 2025-12-26 @ 11:13 AM
NCT ID: NCT00671528
Eligibility Criteria: Inclusion Criteria: * Minimum age: 12 years * Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema). * Diagnosis of impetiginous eczema. * Ability to understand the procedures of the protocol and follow the requirements during the course of the study. * Results of routine laboratory tests - hemogram with leukogram and platelet count, creatinine, glucose, sed. rate, IgE level and transaminases; along with plasma cortisol and adrenocorticotropic hormone (ACTH) levels prior to the start of the treatment. These results must all be within normal limits or not clinically relevant in order to be included in the trial. Exclusion Criteria: * Pregnant participants or women of childbearing age who are not using birth control methods considered reliable by the attending physician. * Participants with a history of hypersensitivity to any of the components of the medication being studied. * Participants in whom the extent or severity of the lesions requires treatment of a different type than what is planned for this trial. * Participants who need any other type of topical or systemic medication during the trial that might affect the course of the disease. * Participants who have been treated with other topical medications during the 14-day period prior to the start of the trial. * Participants who have received systemic corticosteroids or any other immunosuppressant medication during the 28-day period prior to the start of the study.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 12 Years
Study: NCT00671528
Study Brief:
Protocol Section: NCT00671528